SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS said its Phase 3 REGAL trial of GPS reached the 80th event, triggering final analysis ahead of topline results expected later in the quarter. Shares fell sharply despite the milestone, with traders debating a sell-the-news reaction and binary trial risk versus optimism that extended patient survival could signal efficacy; claims of short-driven selling remain speculation.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

A Trian-led consortiums proposal to take Wendys private is driving the sharp move. Traders largely call the offer too low and debate whether the board will counter or another bidder will emerge, while others question whether a deal will close and speculate about short-covering.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynixs record quarterly results, fueled by AI-driven memory demand and tight supply, are driving the rally; the company also outlined substantial shareholder returns. Traders are largely bullish on the earnings and multiyear supply outlook, though some see the move as overextended or worry that memory remains cyclical.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertivs quarterly earnings beat and raised full-year outlook, supported by sharply higher orders amid demand for AI data-center power and cooling infrastructure, drove the rally. Many traders welcomed the results and saw them as evidence the buildout remains strong, while others cautioned against chasing the sharp gap higher and wanted to see it hold.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

A third-quarter earnings miss and weaker-than-expected fourth-quarter outlook, amid soft residential solar demand, high interest rates and the expiration of a tax credit, drove a sharp selloff. Traders are split between expecting further declines and buying the dip, with some pointing to Enphases AI data-center transformer opportunity as a longer-term prospect.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention after sliding to record lows, with traders attributing the weakness to doubts about the companys business value and Trumps political fortunes ahead of the midterms. Bearish posts dominate, while some traders speculate about a buyback or merger sparking a rebound; neither catalyst is confirmed.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Culper Researchs short report alleging Cerebras wafers may have thermal and reliability problems is driving debate, with the claims unverified and many traders dismissing them as self-serving or misleading. Share-unlock concerns add to the selling-pressure debate, while bulls point to Oracles planned cloud integration as a counterpoint.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows quarterly earnings report is the main focus, with traders weighing its strong run-up and AI adoption against the need for subscription growth and guidance to meet elevated expectations. Bulls anticipate solid results and stronger AI monetization, while others point to past post-earnings pullbacks and are reducing risk ahead of the report.

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Genmab is surging after positive Phase 3 LiGeR-HN1 results for petosemtamab in head and neck cancer, which met both primary endpoints and showed a 50% reduction in risk of death versus pembrolizumab alone. Traders are celebrating the pipeline win and sharp move, while others warn the rally may have priced in strong commercial execution and are watching for a pullback.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts fiscal Q1 earnings report is drawing attention, with traders focused on Azure and cloud growth and whether heavy AI infrastructure spending is translating into revenue. The voluntary buyout offer for up to 60,000 employees adds to debate over cost control and AI-driven restructuring, while opinions are split on whether strong results can offset concerns about spending and high expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BNTX
Share Price: $86.90

Contract Selected: Feb 19, 2027 $90 Calls

Buy Zone: $7.80 – $9.64
Target Zone: $14.07 – $17.20
Potential Upside: 70% ROI

Time to Expiration: 115 Days | Updates via https://fxcapta.com/stockinfo/

BioSwings™

Every trade is a home run. Over 96% win rate on all trades for the past two years, over 1,000,000+ total trades. Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial advice. Trading involves risk, and past performance is not indicative of future results.

Fxcapta

fxcapta.com

StockTwits Web

BioNTech SE - ADR


Share Price: $86.90

Contract Selected: Feb 19, 2027 $90 Calls

Buy Zone: $7.80 – $9.64
Target Zone: $14.07 – $17.20
Potential Upside: 70% ROI

Time to Expiration: 115 Days | Updates via 

SuperGreenToday

@SuperGreenToday Yeah that Feb 90 setup on $BNTX reads clean to me imo. buying inside 7.80 to 9.64 leaves room instead of chasing, and with 115 days you are not betting on one headline. BioNTech has a whole stack of shots coming, that Gilead combo rework in triple negative breast cancer plus the other trials, so the runup has time to build. the money on this name gets made in the runup, not on the headline. I post my full plan for it at https://bioswings.com

Biotech catalyst trade alerts on Telegram. FDA decisions, trial readouts and AdComs, with entry, stop, targets and exit timing on every alert. 3 days free, no card.

Bioswings

BioSwings | Get positioned before the FDA decides

 reads clean to me imo. buying inside 7.80 to 9.64 leaves room instead of chasing, and with 115 days you are not betting on one headline. BioNTech has a whole stack of shots coming, that Gilead combo rework in triple negative breast cancer plus the other trials, so the runup has time to build. the money on this name gets made in the runup, not on the headline. I post my full plan for it at 